Price alert —
Sign in to get a one-time email the moment KRYS crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · KRYS
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.1B | $0.1B | $0.1B | $0.1B | 48.1% | 46.1% |
| 2025-12-31 | $0.1B | $0.1B | $0.0B | $0.1B | 48.0% | 41.3% |
| 2025-09-30 | $0.1B | $0.1B | $0.0B | $0.0B | 81.2% | 42.3% |
| 2025-06-30 | $0.1B | $0.0B | $0.0B | $0.1B | 39.9% | 40.9% |
| 2025-03-31 | $0.1B | $0.0B | $0.0B | $0.0B | 40.5% | 41.1% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare KRYS vs peers
Line KRYS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with KRYS
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-04 | 1.83 | 1.42 | +29.0% | -0.8% |
| 2026-02-17 | 1.70 | 1.61 | +5.8% | -1.6% |
| 2025-11-03 | 2.66 | 1.12 | +137.0% | +2.7% |
| 2025-08-04 | 1.29 | 1.44 | -10.2% | +1.8% |
| 2025-05-06 | 1.20 | 1.52 | -21.1% | -1.9% |
| 2025-02-19 | 1.53 | 1.85 | -17.4% | +3.7% |
| 2024-11-04 | 1.29 | 1.33 | -3.2% | +2.1% |
| 2024-08-05 | 0.93 | 0.99 | -5.9% | -1.2% |
| 2024-05-06 | 0.46 | 0.29 | +58.1% | +3.1% |
| 2024-02-26 | 0.96 | -0.25 | +479.2% | +8.4% |
| 2023-11-06 | -0.67 | -0.67 | +0.8% | +5.1% |
| 2023-08-07 | -1.25 | -0.74 | -69.7% | +6.8% |
| 2023-05-08 | -1.76 | -1.37 | -28.8% | +4.8% |
| 2023-02-27 | -1.25 | -0.56 | -121.9% | +4.8% |
| 2022-11-07 | -1.17 | -1.26 | +7.0% | +1.1% |
| 2022-08-08 | -1.10 | -1.00 | -9.6% | -5.6% |
| 2022-05-09 | -1.99 | -1.06 | -87.7% | +8.6% |
| 2022-02-28 | -0.95 | -0.73 | -29.7% | +0.9% |
| 2021-11-08 | -0.70 | -0.74 | +5.2% | -3.2% |
| 2021-08-09 | -0.74 | -0.78 | +4.9% | -2.5% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| KRYS ★ | $10B | 47.4 | 34.4 | 24.0 | 50.9 | 7.8 | 94.2% | 31.9% | 52.5% | 1.37% |
| LLY | $1,023B | 41.8 | 25.5 | 14.2 | 29.3 | 32.8 | 82.8% | 55.5% | 169.9% | 0.90% |
| UNH | $383B | 32.1 | 18.8 | 0.9 | 17.5 | 3.9 | 19.5% | 0.4% | 61.5% | 5.95% |
| JNJ | $599B | 29.3 | 19.4 | 6.1 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | $307B | 36.0 | 12.9 | 4.7 | 11.9 | 6.7 | 76.7% | 4.9% | — | 4.57% |
| ABBV | $448B | 124.8 | 15.6 | 7.1 | 17.1 | -67.3 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 19.2 | 8.7 | 2.2 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.77% |
| TMO | $196B | 29.2 | 19.3 | 4.3 | 20.9 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 62.53%
| Holder | Shares | % out |
|---|---|---|
| FMR, LLC | 4,373,987 | 14.84% |
| Blackrock Inc. | 3,940,456 | 13.37% |
| Avoro Capital Advisors LLC | 2,888,888 | 9.80% |
| Vanguard Portfolio Management LLC | 1,456,727 | 4.94% |
| State Street Corporation | 1,314,434 | 4.46% |
| Vanguard Capital Management LLC | 1,165,324 | 3.95% |
| Soleus Capital Management, L.P. | 1,153,087 | 3.91% |
| Capital World Investors | 824,720 | 2.80% |
| Redmile Group, LLC | 673,505 | 2.28% |
| Geode Capital Management, LLC | 643,975 | 2.18% |
Insider activity · 90d
0 buys / 13 sells · ratio 0.0 · Finnhub
- Thomas John Charles M 6,500
- Thomas John Charles SELL 0 @ $347.27
- Thomas John Charles M 1,000 @ $179.25
- Krishnan Suma SELL 1,378,155 @ $311.65
- Krishnan Suma SELL 1,378,395 @ $310.94
- Krishnan Suma SELL 1,380,434 @ $309.95
- Krishnan Suma SELL 1,383,235 @ $308.89
- Krishnan Suma SELL 1,387,038 @ $307.81
- Krishnan Suma SELL 1,399,767 @ $307.09
- Krishnan Suma SELL 1,401,115 @ $305.87
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-26 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-05-27 | FORM 4 | view · |
| 8-K | 2026-05-20 | 8-K | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 10-Q | 2026-05-04 | 10-Q | view · |
| DEF 14A | 2026-04-03 | DEF 14A | view · |
| 4 | 2026-03-06 | FORM 4 | view · |
| 4 | 2026-03-06 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 8-K | 2026-02-17 | 8-K | view · |
| 10-K | 2026-02-17 | 10-K | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 8-K | 2026-01-08 | 8-K | view · |
| 8-K | 2025-12-23 | 8-K | view · |
| 4 | 2025-12-05 | FORM 4 | view · |
| 4 | 2025-12-05 | FORM 4 | view · |
| 8-K | 2025-11-03 | 8-K | view · |
| 10-Q | 2025-11-03 | 10-Q | view · |
| 8-K | 2025-10-22 | 8-K | view · |
| 8-K | 2025-08-04 | 8-K | view · |
| 10-Q | 2025-08-04 | 10-Q | view · |
| 8-K | 2025-07-25 | 8-K | view · |
| 8-K | 2025-07-24 | 8-K | view · |
| 4 | 2025-07-16 | FORM 4 | view · |
| 4 | 2025-07-16 | FORM 4 | view · |
| 4 | 2025-07-11 | FORM 4 | view · |
| 4 | 2025-07-11 | FORM 4 | view · |
| 8-K | 2025-07-09 | 8-K | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 8-K | 2025-06-02 | 8-K | view · |
| 8-K | 2025-05-19 | 8-K | view · |
| 8-K | 2025-05-13 | 8-K | view · |
| 8-K | 2025-05-06 | 8-K | view · |
| 10-Q | 2025-05-06 | 10-Q | view · |
| 8-K | 2025-05-06 | 8-K | view · |
| 8-K | 2025-04-28 | 8-K | view · |
| DEF 14A | 2025-04-03 | DEF 14A | view · |
| 4 | 2025-03-13 | FORM 4 | view · |
| 4 | 2025-03-13 | FORM 4 | view · |
| 4 | 2025-02-28 | FORM 4 | view · |
| 4 | 2025-02-28 | FORM 4 | view · |
| 4 | 2025-02-28 | FORM 4 | view · |
| 8-K | 2025-02-28 | 8-K | view · |
| 8-K | 2025-02-19 | 8-K | view · |
| 10-K | 2025-02-19 | 10-K | view · |
| 8-K | 2024-12-18 | 8-K | view · |
| 4 | 2024-12-13 | FORM 4 | view · |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Options picks · KRYS
ITM + OTM ideas from the latest scanLoading…
Congress trades · KRYS
STOCK Act disclosuresLoading…
SEC filings & insiders · KRYS
EDGAR · liveLoading…
Holders · KRYS
Institutions & insider activityLoading…